The Drug and Medical Technology Agency have rejected registration of alatrofloxacin because recent studies have shown serious and unpredictable liver injuries after administration of the drug. (Reference: Communication to WHO, 9 August 2000)
Singapore
The National Pharmaceutical Administration in the Ministry of Health has not approved alatrofloxacin since it is associated with hepatic adverse reactions. (Reference: Communication to WHO, 2 August 2000.)